Part 1 - Dr. Marty Heslin talks about the "New Normal" for cancer care

04/23/21 • 18 min

Petauri PACT Executive Briefings - 3-Minute Market Insights

Part 1 - Dr. Marty Heslin talks about the New Normal for cancer care

Dr. Marty Heslin is the new Cancer Center Director for the University of South Alabama Mitchell Cancer Institute in Mobile, Alabama. He is a Surgical Oncologist, and has spent the last 25 years at the University of Alabama at Birmingham Health System, where he most recently served as the Chief of the Medical Staff, and Executive Vice Chair of Surgery.

In this episode we take a look at how the COVID-19 pandemic has changed the delivery of cancer care. 2020 has been a transformative year in many different ways... not all bad... even amid the challenges there have been some tremendously positive innovations and changes that will help us improve patient care for the future. We are all scrambling to understand what the “New Normal” might look like.

In PART 1 of our interview, Dr. Heslin shares his thoughts on how the delivery of cancer care was impacted by the challenges we all faced in 2020. He speaks at length about how patients, hospitals, physicians, and clinical teams reacted to the pandemic and have demonstrated incredible resilience and fortitude throughout this last year. He also shares his findings of what he refers to as a “market research tour” of the cancer centers and hospitals within his new service area, to hear directly from these key stakeholders, what is most important them in the delivery of cancer care and what they need from a clinical partner like the Mitchell Cancer Institute.

Send us a text

Part 1 - Dr. Marty Heslin talks about the New Normal for cancer care

Previous Episode

Part 2 - Examining the Implications of Clinical Pathways on the Oncology Marketplace

Send us a text

Part 2 - Examining the Implications of Clinical Pathways on the Oncology Marketplace
In Part 1 of this conversation, Ron talked about the increasing use of clinical treatment pathways by payers and providers to influence formulary decision making. In Part 2, we continue this discussion with Ron sharing his insights coming from their firm’s syndicated reports, as well as his thoughts on how life science companies should be training their field teams to be navigating these complex issues.
Ron Schleif can be reached at [email protected]

Next Episode

Part 1 - Financial Toxicity in Cancer Care and its Impact on Oral Adherence

Send us a text

Part 1 of 3 - The Burden of Treatment
In today's episode, we begin a 3 part series, exploring how increasing financial toxicity in cancer care is impacting patients’ adherence to self-administered oral medications. Part one defines the term Financial Toxicity and describes the "Total Burden of Treatment" as first reported by Carl May.

A transcript of this podcast, including all of the references, can be found at our website, TKGOncology.com, on our resources page.